Desmetramadol: Difference between revisions
CSV import |
CSV import |
||
| Line 30: | Line 30: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
<gallery> | |||
File:O-desmethyltramadol_racemate2DCSD3.svg | |||
</gallery> | |||
Latest revision as of 22:06, 16 February 2025
Desmetramadol (also known as O-Desmethyltramadol, O-DSMT, or 1-(3-methoxyphenyl)cyclohexanol) is an opioid analgesic and the main active metabolite of tramadol. It is significantly more potent than its parent compound, making it a key player in tramadol's analgesia.
Pharmacology[edit]
Desmetramadol is a mu-opioid receptor agonist, meaning it binds to and activates these receptors in the brain to produce its analgesic effects. It is also a weak norepinephrine and serotonin reuptake inhibitor, which may contribute to its analgesic and mood-altering effects.
Metabolism[edit]
Desmetramadol is formed from tramadol in the liver via the cytochrome P450 enzyme system, specifically the CYP2D6 enzyme. This process, known as O-demethylation, removes a methyl group from tramadol, transforming it into desmetramadol.
Clinical Use[edit]
Desmetramadol is not typically used directly in clinical practice, but its formation in the body is crucial for the effectiveness of tramadol. Some individuals, known as "poor metabolizers," have a less active form of the CYP2D6 enzyme and may not experience the full analgesic effects of tramadol due to reduced formation of desmetramadol.
Side Effects[edit]
As an opioid, desmetramadol can cause a range of side effects, including nausea, vomiting, constipation, drowsiness, and respiratory depression. It also carries a risk of dependence and withdrawal if used for extended periods.
See Also[edit]
